Principles of dendritic cell-based immunotherapy in myeloid leukemia

Immunobiology

Volumn 211, Issue 6-8, 2006, Pages 663-676

  Westers, Theresia M ^a   Houtenbos, Ilse ^a   van de Loosdrecht, Arjan A ^a   Ossenkoppele, Gert J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Chronic myeloid leukemia; Dendritic cells; Immunotherapy

Indexed keywords

ALPHA INTERFERON; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BISMUTH 213; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; IMATINIB; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; IODINE 131; PEPTIDE DERIVATIVE; RADIOISOTOPE; YTTRIUM 90;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL INTERACTION; CELL MIGRATION; CHRONIC GRANULOCYTIC LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LEUKEMIA CELL; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; T LYMPHOCYTE;

EID: 33747365634     PISSN: 01712985     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imbio.2006.06.003     Document Type: Review

References (90)

1. Alegre M.L., Frauwirth K.A., and Thompson C.B. T-cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 1 (2001) 220-228
2. Bachmann M.F., Kopf M., and Marsland B.J. Chemokines: more than just road signs. Nat. Rev. Immunol. 6 (2006) 159-164
3. Banat G.A., Usluoglu N., Hoeck M., Ihlow K., Hoppmann S., and Pralle H. Dendritic cells fused with core binding factor-beta positive acute myeloid leukaemia blast cells induce activation of cytotoxic lymphocytes. Br. J. Haematol. 126 (2004) 593-601
4. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., and Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18 (2000) 767-811
5. Barratt-Boyes S.M., Zimmer M.I., Harshyne L.A., Meyer E.M., Watkins S.C., Capuano III S., Murphey-Corb M., Falo Jr. L.D., and Donnenberg A.D. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J. Immunol. 164 (2000) 2487-2495
6. Bedrosian I., Mick R., Xu S., Nisenbaum H., Faries M., Zhang P., Cohen P.A., Koski G., and Czerniecki B.J. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J. Clin. Oncol. 21 (2003) 3826-3835
7. Bocchia M., Gentili S., Abruzzese E., Fanelli A., Iuliano F., Tabilio A., Amabile M., Forconi F., Gozzetti A., Raspadori D., Amadori S., and Lauria F. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 365 (2005) 657-662
8. Buggins A.G., Milojkovic D., Arno M.J., Lea N.C., Mufti G.J., Thomas N.S., and Hirst W.J. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J. Immunol. 167 (2001) 6021-6030
9. Camporeale A., Boni A., Iezzi G., Degl'Innocenti E., Grioni M., Mondino A., and Bellone M. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res. 63 (2003) 3688-3694
10. Cathcart K., Pinilla-Ibarz J., Korontsvit T., Schwartz J., Zakhaleva V., Papadopoulos E.B., and Scheinberg D.A. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103 (2004) 1037-1042
11. Caux C., Dezutter-Dambuyant C., Schmitt D., and Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360 (1992) 258-261
12. Chamuleau M.E., Souwer Y., Van Ham S.M., Zevenbergen A., Westers T.M., Berkhof J., Meijer C.J., van de Loosdrecht A.A., and Ossenkoppele G.J. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res. 64 (2004) 5546-5550
13. Choudhury A., Gajewski J.L., Liang J.C., Popat U., Claxton D.F., Kliche K.O., Andreeff M., and Champlin R.E. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89 (1997) 1133-1142
14. Cignetti A., Vallario A., Roato I., Circosta P., Allione B., Casorzo L., Ghia P., and Caligaris-Cappio F. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J. Immunol. 173 (2004) 2855-2865
15. Curti A., Pandolfi S., Aluigi M., Isidori A., Alessandrini I., Chiodoni C., Testoni N., Colombo M.P., Baccarani M., and Lemoli R.M. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. Exp. Hematol. 33 (2005) 1521-1530
16. Czerniecki B.J., Carter C., Rivoltini L., Koski G.K., Kim H.I., Weng D.E., Roros J.G., Hijazi Y.M., Xu S., Rosenberg S.A., and Cohen P.A. Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J. Immunol. 159 (1997) 3823-3837
17. Davis T.A., Saini A.A., Blair P.J., Levine B.L., Craighead N., Harlan D.M., June C.H., and Lee K.P. Phorbol esters induce differentiation of human CD34+ hemopoietic progenitors to dendritic cells: evidence for protein kinase C-mediated signaling. J. Immunol. 160 (1998) 3689-3697
18. de Gruijl T.D., Luykx-de Bakker S.A., Tillman B.W., van den Eertwegh A.J., Buter J., Lougheed S.M., van der Bij G.J., Safer A.M., Haisma H.J., Curiel D.T., Scheper R.J., Pinedo H.M., and Gerritsen W.R. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J. Immunol. 169 (2002) 5322-5331
19. de Vries I.J., Krooshoop D.J., Scharenborg N.M., Lesterhuis W.J., Diepstra J.H., Van Muijen G.N., Strijk S.P., Ruers T.J., Boerman O.C., Oyen W.J., Adema G.J., Punt C.J., and Figdor C.G. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63 (2003) 12-17
20. de Vries I.J., Lesterhuis W.J., Barentsz J.O., Verdijk P., van Krieken J.H., Boerman O.C., Oyen W.J., Bonenkamp J.J., Boezeman J.B., Adema G.J., Bulte J.W., Scheenen T.W., Punt C.J., Heerschap A., and Figdor C.G. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat. Biotechnol. 23 (2005) 1407-1413
21. Di Bacco A., Keeshan K., McKenna S.L., and Cotter T.G. Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis. Oncologist 5 (2000) 405-415
22. Diehl L., den Boer A.T., Schoenberger S.P., van der Voort E.I., Schumacher T.N., Melief C.J., Offringa R., and Toes R.E. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5 (1999) 774-779
23. Dong R., Cwynarski K., Entwistle A., Marelli-Berg F., Dazzi F., Simpson E., Goldman J.M., Melo J.V., Lechler R.I., Bellantuono I., Ridley A., and Lombardi G. Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood 101 (2003) 3560-3567
24. Dranoff G. GM-CSF-based cancer vaccines. Immunol. Rev. 188 (2002) 147-154
25. Eisendle K., Lang A., Eibl B., Nachbaur D., Glassl H., Fiegl M., Thaler J., and Gastl G. Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br. J. Haematol. 120 (2003) 63-73
26. Fagnoni F.F., Lozza L., Zibera C., Zambelli A., Ponchio L., Gibelli N., Oliviero B., Pavesi L., Gennari R., Vescovini R., Sansoni P., Da Prada G., and Robustelli Della C.G. T-cell dynamics after high-dose chemotherapy in adults: elucidation of the elusive CD8+ subset reveals multiple homeostatic T-cell compartments with distinct implications for immune competence. Immunology 106 (2002) 27-37
27. Feller N., van der Pol M.A., van Stijn A., Weijers G.W., Westra A.H., Evertse B.W., Ossenkoppele G.J., and Schuurhuis G.J. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18 (2004) 1380-1390
28. Figdor C.G., de Vries I.J., Lesterhuis W.J., and Melief C.J. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10 (2004) 475-480
29. Galea-Lauri J., Darling D., Mufti G., Harrison P., and Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother. 51 (2002) 299-310
30. Harrison B.D., Adams J.A., Briggs M., Brereton M.L., and Yin J.A. Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia. Blood 97 (2001) 2764-2771
31. Houtenbos I., Westers T.M., Ossenkoppele G.J., and van de Loosdrecht A.A. Identification of CD14 as a predictor for leukemic dendritic cell differentiation in acute myeloid leukemia. Leukemia 17 (2003) 1683-1684
32. Houtenbos I., Westers T.M., Stam A.G., de Gruijl T.D., Scheper R.J., Ossenkoppele G.J., and van de Loosdrecht A.A. Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation. Cancer Immunol. Immunother. 52 (2003) 455-462
33. Houtenbos I., Westers T.M., de Gruijl T.D., Scheper R.J., Ossenkoppele G.J., and van de Loosdrecht A.A. TNF-alpha receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells. Leukemia 18 (2004) 1149-1153
34. Houtenbos I., Westers T.M., Ossenkoppele G.J., and van de Loosdrecht A.A. Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization. Immunobiology 210 (2005) 249-257
35. Houtenbos I., Westers T.M., Ossenkoppele G.J., and van de Loosdrecht A.A. Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. Immunobiology 211 (2006) 675-683
36. Illmer T., Schaich M., Platzbecker U., Freiberg-Richter J., Oelschlagel U., von Bonin M., Pursche S., Bergemann T., Ehninger G., and Schleyer E. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18 (2004) 401-408
37. Ishii K., Kurita-Taniguchi M., Aoki M., Kimura T., Kashiwazaki Y., Matsumoto M., and Seya T. Gene-inducing program of human dendritic cells in response to BCG cell-wall skeleton (CWS), which reflects adjuvancy required for tumor immunotherapy. Immunol. Lett. 98 (2005) 280-290
38. Ito F., Li Q., Shreiner A.B., Okuyama R., Jure-Kunkel M.N., Teitz-Tennenbaum S., and Chang A.E. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 64 (2004) 8411-8419
39. Kalinski P., Giermasz A., Nakamura Y., Basse P., Storkus W.J., Kirkwood J.M., and Mailliard R.B. Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol. Immunol. 42 (2005) 535-539
40. Kapsenberg M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3 (2003) 984-993
41. Lee J.J., Kook H., Park M.S., Nam J.H., Choi B.H., Song W.H., Park K.S., Lee I.K., Chung I.J., Hwang T.J., and Kim H.J. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation. J. Clin. Apheresis 19 (2004) 66-70
42. Li L., Reinhardt P., Schmitt A., Barth T.F., Greiner J., Ringhoffer M., Dohner H., Wiesneth M., and Schmitt M. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol. Immunother. 54 (2005) 685-693
43. Marijt W.A., Heemskerk M.H., Kloosterboer F.M., Goulmy E., Kester M.G., van der Hoorn M.A., Luxemburg-Heys S.A., Hoogeboom M., Mutis T., Drijfhout J.W., van Rood J.J., Willemze R., and Falkenburg J.H. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl. Acad. Sci. USA 100 (2003) 2742-2747
44. Martin-Fontecha A., Sebastiani S., Hopken U.E., Uguccioni M., Lipp M., Lanzavecchia A., and Sallusto F. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. 198 (2003) 615-621
45. Martin-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., and Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 5 (2004) 1260-1265
46. McKenna S.L., and Cotter T.G. Functional aspects of apoptosis in hematopoiesis and consequences of failure. Adv. Cancer Res. 71 (1997) 121-164
47. Melero I., Shuford W.W., Newby S.A., Aruffo A., Ledbetter J.A., Hellstrom K.E., Mittler R.S., and Chen L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3 (1997) 682-685
48. Mohty M., Jarrossay D., Lafage-Pochitaloff M., Zandotti C., Briere F., de Lamballeri X.N., Isnardon D., Sainty D., Olive D., and Gaugler B. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 98 (2001) 3750-3756
49. Mohty M., Isnardon D., Blaise D., Mozziconacci M.J., Lafage-Pochitaloff M., Briere F., Gastaut J.A., Olive D., and Gaugler B. Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia. Leukemia 16 (2002) 2267-2274
50. Molldrem J.J., Lee P.P., Wang C., Felio K., Kantarjian H.M., Champlin R.E., and Davis M.M. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med. 6 (2000) 1018-1023
51. Molldrem J.J., Lee P.P., Kant S., Wieder E., Jiang W., Lu S., Wang C., and Davis M.M. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111 (2003) 639-647
52. Morse M.A., Coleman R.E., Akabani G., Niehaus N., Coleman D., and Lyerly H.K. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59 (1999) 56-58
53. Nair S., McLaughlin C., Weizer A., Su Z., Boczkowski D., Dannull J., Vieweg J., and Gilboa E. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171 (2003) 6275-6282
54. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., and Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4 (1998) 328-332
55. O'Neill D.W., Adams S., and Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 104 (2004) 2235-2246
56. Osman Y., Takahashi M., Zheng Z., Toba K., Liu A., Furukawa T., Narita M., Aizawa Y., Koike T., and Shibata A. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J. Exp. Clin. Cancer Res. 18 (1999) 485-492
57. Ossenkoppele G.J., Stam A.G., Westers T.M., de Gruijl T.D., Janssen J.J., van de Loosdrecht A.A., and Scheper R.J. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 17 (2003) 1424-1426
58. Phan G.Q., Yang J.C., Sherry R.M., Hwu P., Topalian S.L., Schwartzentruber D.J., Restifo N.P., Haworth L.R., Seipp C.A., Freezer L.J., Morton K.E., Mavroukakis S.A., Duray P.H., Steinberg S.M., Allison J.P., Davis T.A., and Rosenberg S.A. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100 (2003) 8372-8377
59. Portielje J.E., Kruit W.H., Eerenberg A.J., Schuler M., Sparreboom A., Lamers C.H., Gratama J.W., Stoter G., Huber C., and Hack C.E. Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant. Cancer Immunol. Immunother. 54 (2005) 37-43
60. Powles R.L., Russell J., Lister T.A., Oliver T., Whitehouse J.M., Malpas J., Chapuis B., Crowther D., and Alexander P. Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient. Br. J. Cancer 35 (1977) 265-272
61. Ribas A., Glaspy J.A., Lee Y., Dissette V.B., Seja E., Vu H.T., Tchekmedyian N.S., Oseguera D., Comin-Anduix B., Wargo J.A., Amarnani S.N., McBrid W.H., Economou J.S., and Butterfield L.H. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J. Immunother. 27 (2004) 354-367
62. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 21 (2003) 873-886
63. Salgia R., Quackenbush E., Lin J., Souchkova N., Sattler M., Ewaniuk D.S., Klucher K.M., Daley G.Q., Kraeft S.K., Sackstein R., Alyea E.P., von Andrian U.H., Chen L.B., Gutierrez-Ramos J.C., Pendergast A.M., and Griffin J.D. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 94 (1999) 4233-4246
64. Sallusto F., and Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179 (1994) 1109-1118
65. Sallusto F., Schaerli P., Loetscher P., Schaniel C., Lenig D., Mackay C.R., Qin S., and Lanzavecchia A. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 28 (1998) 2760-2769
66. Saudemont A., and Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis. Blood 104 (2004) 2124-2133
67. Saudemont A., Jouy N., Hetuin D., and Quesnel B. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells. Blood 105 (2005) 2428-2435
68. Scheibenbogen C., Letsch A., Thiel E., Schmittel A., Mailaender V., Baerwolf S., Nagorsen D., and Keilholz U. CD8 T-cell responses to Wilms' tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100 (2002) 2132-2137
69. Schimmer A.D., Pedersen I.M., Kitada S., Eksioglu-Demiralp E., Minden M.D., Pinto R., Mah K., Andreeff M., Kim Y., Suh W.S., and Reed J.C. Functional blocks in caspase activation pathways are common in leukemia and predict patient response to induction chemotherapy. Cancer Res. 63 (2003) 1242-1248
70. Seggewiss R., Lore K., Greiner E., Magnusson M.K., Price D.A., Douek D.C., Dunbar C.E., and Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105 (2005) 2473-2479
71. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., and Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64 (2004) 6337-6343
72. Shimizu K., Fields R.C., Giedlin M., and Mule J.J. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA 96 (1999) 2268-2273
73. Smith M., Barnett M., Bassan R., Gatta G., Tondini C., and Kern W. Adult acute myeloid leukaemia. Crit. Rev. Oncol. Hematol. 50 (2004) 197-222
74. Spisek R., Chevallier P., Morineau N., Milpied N., Avet-Loiseau H., Harousseau J.L., Meflah K., and Gregoire M. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. Cancer Res. 62 (2002) 2861-2868
75. Stam A.G., Santegoets S.J., Westers T.M., Sombroek C.C., Janssen J.J., Tillman B.W., van de Loosdrecht A.A., Pinedo H.M., Curiel D.T., Ossenkoppele G.J., Scheper R.J., and de Gruijl T.D. CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation. Br. J. Cancer 89 (2003) 1162-1165
76. Sun J.Y., Krouse R.S., Forman S.J., Senitzer D., Sniecinski I., Chatterjee S., and Wong Jr. K.K. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res. 62 (2002) 3175-3183
77. Sussman J.J., Parihar R., Winstead K., and Finkelman F.D. Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion. Cancer Res. 64 (2004) 9124-9130
78. Tourneur L., Delluc S., Levy V., Valensi F., Radford-Weiss I., Legrand O., Vargaftig J., Boix C., Macintyre E.A., Varet B., Chiocchia G., and Buzyn A. Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome. Cancer Res. 64 (2004) 8101-8108
79. Van der Pol M.A., Feller N., Ossenkoppele G.J., Weijers G.W., Westra A.H., van Stijn A., Broxterman H.J., and Schuurhuis G.J. Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis. Leukemia 17 (2003) 1674-1677
80. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 (2002) 2292-2302
81. Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat. Immunol. 5 (2004) 685-692
82. Westers T.M., Stam A.G., Scheper R.J., Regelink J.C., Nieuwint A.W., Schuurhuis G.J., van de Loosdrecht A.A., and Ossenkoppele G.J. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cancer Immunol. Immunother. 52 (2003) 17-27
83. Westers T.M., Houtenbos I., van de Loosdrecht A.A., and Ossenkoppele G.J. Divergent autologous T cell responses to leukaemic dendritic cells during remission in acute promyelocytic leukaemia. Cell Oncol. 27 (2005) 261-266
84. Westers T.M., Houtenbos I., Snoijs N.C., van de Loosdrecht A.A., and Ossenkoppele G.J. Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity. Leukemia 19 (2005) 1270-1272
85. Westers T.M., Janssen J.J., Houtenbos I., Snoijs N.C., van de Loosdrecht A.A., and Ossenkoppele G.J. Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of Imatinib mesylate: implication for vaccination regimens. Leukemia 20 (2006) 154-157
86. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., and Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9 (2003) 606-612
87. Wu F., Oka Y., Tsuboi A., Elisseeva O.A., Ogata K., Nakajima H., Fujiki F., Masuda T., Murakami M., Yoshihara S., Ikegame K., Hosen N., Kawakami M., Nakagawa M., Kubota T., Soma T., Yamagami T., Tsukaguchi M., Ogawa H., Oji Y., Hamaoka T., Kawase I., and Sugiyama H. Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia 19 (2005) 268-274
88. Yang L., and Carbone D.P. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 92 (2004) 13-27
89. Yu P., Spiotto M.T., Lee Y., Schreiber H., and Fu Y.X. Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J. Exp. Med. 197 (2003) 985-995
90. Zhang W.G., Liu S.H., Cao X.M., Cheng Y.X., Ma X.R., Yang Y., and Wang Y.L. A phase-I clinical trial of active immunotherapy for acute leukemia using inactivated autologous leukemia cells mixed with IL-2, GM-CSF, and IL-6. Leuk. Res. 29 (2005) 3-9